Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1976 1
1978 1
1980 1
1981 1
1984 1
1985 2
1986 2
1987 1
1988 3
1989 2
1990 4
1991 3
1992 6
1993 3
1994 9
1995 7
1996 5
1997 13
1998 17
1999 7
2000 11
2001 25
2002 23
2003 21
2004 20
2005 28
2006 27
2007 24
2008 25
2009 22
2010 23
2011 33
2012 28
2013 28
2014 17
2015 29
2016 21
2017 22
2018 19
2019 14
2020 23
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

531 results
Results by year
Filters applied: . Clear all
Page 1
Oxybutynin as an alternative treatment for hyperhidrosis.
Delort S, Marchi E, Corrêa MA. Delort S, et al. An Bras Dermatol. 2017 Mar-Apr;92(2):217-220. doi: 10.1590/abd1806-4841.201755126. An Bras Dermatol. 2017. PMID: 28538882 Free PMC article. Review.
The aim of this review is to focus on the treatment of hyperhidrosis with oxybutynin, an anticholinergic drug originally used to control overactive bladder....
The aim of this review is to focus on the treatment of hyperhidrosis with oxybutynin, an anticholinergic drug originally used to cont …
Oxybutynin.
Dwyer J, Tafuri SM, LaGrange CA. Dwyer J, et al. 2021 Jul 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 Jul 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 29763161 Free Books & Documents. Review.
Oxybutynin is an anticholinergic medication that is indicated in patients with overactive bladder or symptoms of detrusor overactivity, including urinary frequency and urgency. ...This activity outlines the indications, mechanism of action, methods of administration, impor
Oxybutynin is an anticholinergic medication that is indicated in patients with overactive bladder or symptoms of detrusor overactivit
Drugs for menopausal symptoms.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Aug 10;62(1604):124-128. Med Lett Drugs Ther. 2020. PMID: 32960867 Corrected and republished. Review. No abstract available.
[Oxybutynin-Kentera].
Duh D, Vandevijver A. Duh D, et al. J Pharm Belg. 2007;62(3):99-100. J Pharm Belg. 2007. PMID: 17955962 French. No abstract available.
S-oxybutynin.
[No authors listed] [No authors listed] Drugs R D. 2002;3(2):84-5. doi: 10.2165/00126839-200203020-00003. Drugs R D. 2002. PMID: 12001823 No abstract available.
Tolerance of oral oxybutynin in the treatment of hyperhidrosis.
Del Boz Gonzalez J, Rodríguez Barón D, Millán-Cayetano JF, de Troya Martin M. Del Boz Gonzalez J, et al. Dermatol Ther. 2020 Nov;33(6):e14197. doi: 10.1111/dth.14197. Epub 2020 Sep 7. Dermatol Ther. 2020. PMID: 32794595
Oral oxybutynin (OOx) is an effective and safe treatment for the treatment of hyperhidrosis (HH). ...
Oral oxybutynin (OOx) is an effective and safe treatment for the treatment of hyperhidrosis (HH). ...
Oxybutynin in primary hyperhidrosis: A long-term real-life study.
Almeida ART, Ferrari F, Restrepo MVS, Rocha VB. Almeida ART, et al. Dermatol Ther. 2020 Nov;33(6):e14344. doi: 10.1111/dth.14344. Epub 2020 Oct 5. Dermatol Ther. 2020. PMID: 32981151
In a real-life long-term study, 30 patients with primary hyperhidrosis and Hyperhidrosis Disease Severity Scale (HDSS) with score of at least two were submitted to a questionnaire to assess demographic data, HDSS and side effects of oxybutynin. Most patients were wo …
In a real-life long-term study, 30 patients with primary hyperhidrosis and Hyperhidrosis Disease Severity Scale (HDSS) with score of at leas …
Oxybutynin topical gel in the treatment of overactive bladder.
Davila GW. Davila GW. Open Access J Urol. 2010 Jun 16;2:91-8. Open Access J Urol. 2010. PMID: 24198618 Free PMC article. Review.
This has been attributed in part to the occurrence of dry mouth and other anticholinergic adverse events. High plasma concentrations of N-desethyloxybutynin (DEO), an active metabolite of oxybutynin, have been identified as the major cause of anticholinergic adve
This has been attributed in part to the occurrence of dry mouth and other anticholinergic adverse events. High plasma concentrations …
Oxybutynin topical and transdermal formulations: an update.
Staskin DR, Salvatore S. Staskin DR, et al. Drugs Today (Barc). 2010 Jun;46(6):417-25. doi: 10.1358/dot.2010.46.6.1487750. Drugs Today (Barc). 2010. PMID: 20571610 Review.
Although oral oxybutynin is effective in relieving the urinary symptoms of OAB, medication adherence is low at least in part because of substantial anticholinergic adverse effects. ...Oxybutynin chloride topical gel (OTG) (Gelnique(R), Watson Pharmaceu …
Although oral oxybutynin is effective in relieving the urinary symptoms of OAB, medication adherence is low at least in part because …
Extended-release oxybutynin.
Comer AM, Goa KL. Comer AM, et al. Drugs Aging. 2000 Feb;16(2):149-55; discussion 156-7. doi: 10.2165/00002512-200016020-00008. Drugs Aging. 2000. PMID: 10755330 Review.
Mean peak plasma concentrations are lower with extended-release oxybutynin 15mg once daily than with conventional immediate-release oxybutynin 5mg taken 3 times daily. ...Extended-release oxybutynin had similar efficacy to immediate-release oxybutynin. …
Mean peak plasma concentrations are lower with extended-release oxybutynin 15mg once daily than with conventional immediate-release …
531 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page